Literature DB >> 15279083

Fatal toxic epidermal necrolysis in autoimmune polyglandular syndrome type I.

A Porzionato1, S Zancaner, C Betterle, S D Ferrara.   

Abstract

Autoimmune polyglandular syndrome Type I (APS I) is a disorder defined by the presence of at least two of the following diseases: Addison's disease, hypoparathyroidism, and chronic mucocutaneous candidiasis. We present the case of a 45-yr-old woman, affected by APS I, in chronic treatment with betamethasone. She was referred to a Division of General Medicine for jaundice, ascites and peripheral edema attributed to worsening of pre-existing autoimmune chronic hepatitis. During hospitalization, the following drugs were given: Amoxicillin/Clavulanic acid and Levofloxacin for bronchopneumonia, Furosemide and Canreonate for renal impairment, Pantoprazole for gastric protection, and Itraconazole for oral candidiasis. After about a month, she developed widespread, sheet-like, epidermal detachment, with painful lesions of the conjunctiva, lips and mouth. Toxic epidermal necrolysis (TEN) was diagnosed, and the patient was transferred to a Burn Center, where she died 10 days after the first onset of cutaneous rash. Autoptic and histopathological findings (epidermal necrosis and detachment, lymphomonocytic infiltration of the dermis) confirmed the clinical diagnosis. TEN is a usually drug-induced cutaneous inflammatory disorder characterized by extensive epidermal detachment and frequent mucosal involvement. It has also been associated with immuno-mediated disorders (HIV infection, graft-vs-host disease, systemic lupus erythematosus, mixed essential cryoglobulinemia), in keeping with immuno-mediated pathogenesis. We present, to our knowledge, the first report of TEN in a patient with APS I, and suggest that some pathogenetic mechanisms of APS I are shared with TEN. We stress how such a disease can occur in an autoimmune syndrome, even during corticosteroid treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15279083     DOI: 10.1007/BF03345295

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Polyglandular autoimmune syndrome type II associated with oral lichen planus.

Authors:  Michele Davido Mignogna; Stefano Fedele; Lucio Lo Russo; Elvira Ruoppo; Lorenzo Lo Muzio
Journal:  Int J Dermatol       Date:  2002-04       Impact factor: 2.736

Review 2.  Toxic epidermal necrolysis (Lyell syndrome).

Authors:  J C Roujeau; O Chosidow; P Saiag; J C Guillaume
Journal:  J Am Acad Dermatol       Date:  1990-12       Impact factor: 11.527

Review 3.  Clinical review 93: Autoimmune polyglandular syndrome type 1.

Authors:  C Betterle; N A Greggio; M Volpato
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

4.  Toxic epidermal necrolysis in a patient affected by mixed essential cryoglobulinemia.

Authors:  A Solinas; F Cottoni; F Tanda; A Tocco
Journal:  J Am Acad Dermatol       Date:  1988-05       Impact factor: 11.527

5.  Mycoplasma pneumoniae and the erythema multiforme--Stevens Johnson syndrome.

Authors:  J G McCormack
Journal:  J Infect       Date:  1981-03       Impact factor: 6.072

6.  Toxic epidermal necrolysis in patients receiving glucocorticosteroids.

Authors:  B Rzany; H Schmitt; E Schöpf
Journal:  Acta Derm Venereol       Date:  1991       Impact factor: 4.437

Review 7.  Autoimmune regulator (AIRE) gene on chromosome 21: implications for autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) any more common manifestations of endocrine autoimmunity.

Authors:  G Meyer; K Badenhoop
Journal:  J Endocrinol Invest       Date:  2002-10       Impact factor: 4.256

Review 8.  Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes.

Authors:  M Neufeld; N K Maclaren; R M Blizzard
Journal:  Medicine (Baltimore)       Date:  1981-09       Impact factor: 1.889

Review 9.  An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods.

Authors:  J P Kelly; A Auquier; B Rzany; L Naldi; S Bastuji-Garin; O Correia; S Shapiro; D W Kaufman
Journal:  J Clin Epidemiol       Date:  1995-09       Impact factor: 6.437

10.  Stevens-Johnson syndrome and toxic epidermal necrolysis in a patient with systemic lupus erythematosus.

Authors:  S M Burge; R P Dawber
Journal:  J Am Acad Dermatol       Date:  1985-10       Impact factor: 11.527

View more
  1 in total

1.  Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients.

Authors:  S Garelli; M Dalla Costa; C Sabbadin; S Barollo; B Rubin; R Scarpa; S Masiero; A Fierabracci; C Bizzarri; A Crinò; M Cappa; M Valenzise; A Meloni; A M De Bellis; C Giordano; F Presotto; R Perniola; D Capalbo; M C Salerno; A Stigliano; G Radetti; V Camozzi; N A Greggio; F Bogazzi; I Chiodini; U Pagotto; S K Black; S Chen; B Rees Smith; J Furmaniak; G Weber; F Pigliaru; L De Sanctis; C Scaroni; C Betterle
Journal:  J Endocrinol Invest       Date:  2021-05-18       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.